Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiling of hippocampus from a zQ175 KI mouse model of Huntington's disease treated with either HTT-10150 siRNA targeting full-length HTT or combination of HTT-634 and HTT-486 siRNAs targeting HTT1a

ABSTRACT: In this study, we conducted a comprehensive transcriptional profiling of the hippocampus utilizing a zQ175 knock-in (KI) mouse model of Huntington's disease, which was treated with either HTT-10150 siRNA specifically designed to target the full-length huntingtin (Htt) mRNA or combination of HTT-634 and HTT-486 siRNAs targeting HTT1a. Our investigation aimed to assess the impact of this intervention across different time points.

ORGANISM(S): Mus musculus

PROVIDER: GSE284500 | GEO | 2026/05/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptional profiling of striatum from a zQ175 KI mouse model of Huntington's disease treated with HTT-10150 siRNA targeting full-length Htt

Project description:In this study we conducted a comprehensive transcriptional profiling of the striatum utilizing a zQ175 knock-in (KI) mouse model of Huntington's disease, which was treated with HTT-10150 siRNA specifically designed to target the full-length huntingtin (Htt) mRNA. Our investigation aimed to assess the impact of this intervention across different time points.

2026-05-05 | GSE284497 | GEO

Transcriptional profiling of striatum from a zQ175 KI mouse model of Huntington's disease with or without homozygous knockout of the Msh3 gene

Project description:Previous studies have suggested a strong association between lower MSH3 expression, reduced somatic repeat expansion, and slower disease onset and progression. The effects of a homozygous knock-out in the Msh3 gene on transcriptome phenotypes in striatum in six-month-old WT and zQ175 mice were studied. Striatum was isolated from 6-month-old mice. Transcriptomic analysis (RNASeq) was performed on four genotypes with 8 replicates per genotype: WT (WT for Htt and Msh3), zQ175 (zQ175 for Htt, WT for Msh3), WT.Msh3.HOM (WT for Htt, Homozygous for Msh3 KO), and zQ175.Msh3.HOM (zQ175 for Htt, Homozygous for Msh3 KO).

2024-05-24 | GSE245510 | GEO

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

Project description:The development of drug resistance is still a major impediment for the successful treatment of cancer, such as advanced stage ovarian cancer, which has a 5-year survival rate of only 30%. The molecular processes that contribute to resistance have been extensively studied, however, not much is known about the role of microRNAs. We compared microRNA expression profiles of three isogenic cisplatin sensitive and resistant cell line pairs. The only microRNA that was consistently downregulated (FDR = 0.000) in all resistant cell lines was miR-634. We investigated the effects of miR-634 modulation in ovarian cancer cell lines and patient derived tumor cells. Overexpression of miR-634 gave rise to a modest G1 phase block and enhanced apoptosis. Furthermore, miR-634 resensitized resistant ovarian cancer cell lines and patient derived tumor cells to cisplatin chemotherapy. Similarly, miR-634 enhanced the response of tumor cells to carboplatin and doxorubicin, but not to paclitaxel. We showed that miR-634 regulates cyclin D1 (CCND1), which is required for the G1-S phase transition, explaining the effects on the cell cycle. In addition, miR-634 repressed expression of GRB2, ERK2, RSK1 and RSK2, components of the Ras-MAPK pathway. Altogether, our findings suggest that miR-634 modulates several cancer relevant targets and therefore miR-634 is an attractive therapeutic candidate to resensitize chemotherapy resistant ovarian tumors.

2014-02-04 | GSE54665 | GEO

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

2014-02-04 | E-GEOD-54665 | biostudies-arrayexpress

miR-486-5p inhibits eNOS and angiogenesis in cultured endothelial cells by targeting MAML3

Project description:Kidney ischemia-reperfusion injury (IR) is associated with endothelial injury. Administration of miR-486-5p protects against rat kidney IR injury, with localization to capillary endothelial cells, although it inhibits IR-induced endothelial nitric oxide synthase (eNOS) protein expression. We studied the effects of miR-486-5p on eNOS and endothelial cell function and determined its mRNA targets. Methods: Human umbilical vein endothelial cells (HUVECs) were transfected with miR-486-5p and assayed for proliferation, migrartion, and network formation. Biotinylated miR-486-5p was transfected for pull-down of bound mRNA, followed by RNA sequencing. Results: miR-486-5p markedly decreased eNOS mRNA and protein in HUVECs, although eNOS mRNA was not found to be a direct target of miR-486-5p. miR-486-5p inhibited angiogenesis, which was rescued with eNOS plasmid transfection. RNA sequencing of biotinylated miR-486-5p pull-down RNA revealed highly significant enrichmenet in predicted targets FOXO1, FOXP1, TNFSF4, MAML3, and CELSR3, and in the non-predicted target SPCS2. RT-qPCR validated these transcripts as inhibited miR-486-5p. While silencing of FOXO1 had no impact on eNOS protein, MAML3 silencing inhibited eNOS levels. Conclusion: miR-486-5p inhibits angiogenesis in endothelial cells via down-regulation of eNOS, which involves selective targeting of MAML3. These data support a novel pathway regulating endothelial cell function.

2025-06-04 | GSE281065 | GEO

Genes altered by miR-634 in three cancer cell lines

Project description:To identify genes affected by miR-634 overexpression, we transfected with 20nmol of miR-634 or miR-negative control (NC) in HeLa, KYSE850, or U2OS cells. After 2 days, RNA was extracted, and then expression analysis was performed using agilent microarray.

2015-08-06 | GSE71742 | GEO

Genes altered by miR-634 in three cancer cell lines

2015-08-06 | E-GEOD-71742 | biostudies-arrayexpress

Klebsiella variicola CAG:634

Project description:Klebsiella variicola CAG:634 overview

| PRJNA207271 | ENA

Expression data from Human Fetal Astrocytes and Neurons transduced with WT and mutant HTT

Project description:Glial pathology has been implicated as a causal contributor to the dysfunction and death of striatal neurons that characterizes Huntington disease. In this study, we investigated mutant HTT (mHTT)-associated changes in gene expression by both mouse and human striatal astrocytes. Mouse striatal astrocytes were FACS-sorted from two distinct models, R6/2 and zQ175 mice, which respectively express exon1-only truncated or full-length HTT, while human astrocytes were generated from either hESCs expressing full-length mHTT, or fetal striatal glia transduced with exon1-only mHTT. Comparison of differential gene expression between each of these conditions and their normal HTT controls, and to one another, revealed astrocyte-specific alterations in both truncated and full-length mHTT models that were shared by both species, yet with differences that clearly distinguished glia derived from each model. Overlap of these data sets revealed that the patterns of mHTT-associated transcriptional dysregulation depended not only upon species, but also upon whether the astroglia expressed truncated or full-length mHTT. These data revealed a common set of conserved, mHTT-associated dysregulated pathways that may present targets for the rescue of glial pathology in HD, while revealing that the gene expression of glia expressing truncated mHTT may differ substantially from that of glia expressing full-length mHTT.

2021-04-07 | GSE154128 | GEO

Neisseria gonorrhoeae strain:634

Project description:Neisseria gonorrhoeae strain:634 Genome sequencing

| PRJNA1281293 | ENA